This study examines how reversal of poly(ADP-ribosyl)ation influences nuclear behaviour of PARP1 during DNA damage and replication. The authors show that inhibition of poly(ADP-ribose) glycohydrolase (PARGi) lengthens PARP1 residence on damaged chromatin through a mechanism distinct from conventional PARP-inhibitor trapping. PARG inhibition causes formation of PAR-driven, FUS-enriched PARP1 nuclear condensates after DNA damage. Separately, unrestrained S-phase PARylation during Okazaki fragment maturation triggers PARP1 condensation in a way that reflects intrinsic sensitivity to PARG inhibition. Co-inhibition of FEN1 augments both condensate formation and cytotoxicity. Finally, the authors report that dePARylation prevents rapid nuclear extrusion of PARP1 when cells enter S phase; this extrusion is reversible and could interfere with PARP1-dependent nuclear processes. The work positions dePARylation as a key restraining mechanism that precludes replication-driven PARP1 condensation and highlights Okazaki fragment maturation as a potential therapeutic vulnerability.
The authors report that treatment with PARG inhibitors prolongs the residence time of PARP1 at sites of DNA damage. This prolonged association is described as mechanistically distinct from PARP-trapping induced by conventional PARP inhibitors. Rather than canonical trapping, the prolonged residence correlates with formation of higher-order assemblies that are driven by PAR. The abstract indicates that PARG inhibition therefore stabilizes PARP1 at damaged chromatin through PAR-dependent condensate formation rather than classic active-site inhibition phenomena.
Following DNA damage in the presence of PARG inhibition, the study finds formation of nuclear condensates characterized by PAR-dependent recruitment of proteins and enrichment for the RNA-binding protein FUS. These condensates contain PARP1 and are described as PAR-driven. The presence of FUS within these condensates is highlighted, indicating a specific biochemical composition linked to PAR-dependent phase separation or condensation of PARP1-containing complexes.
The authors observed that unrestrained S-phase PARylation, specifically during Okazaki fragment maturation, also elicits PARP1 condensation. This replication-coupled condensation is reported to mirror intrinsic sensitivity to PARG inhibition, suggesting that the physiological process of Okazaki fragment processing can drive PARP1 condensation when dePARylation is impaired. The findings implicate DNA replication intermediates and the maturation of lagging-strand fragments as contexts in which elevated PARylation can nucleate PARP1 condensation.
Co-inhibition of FEN1, a nuclease involved in Okazaki fragment processing, was found to potentiate both the formation of PARP1 condensates and cellular cytotoxicity in the presence of impaired dePARylation. This result links a specific replication-processing factor to the magnitude of PAR-driven condensation and to viability outcomes, identifying a combinatorial interaction between replication stress on the lagging strand and dePARylation status.
A novel observation reported is that dePARylation prevents rapid nuclear extrusion of PARP1 when cells enter S phase. In the absence of effective dePARylation, PARP1 undergoes a prompt nuclear extrusion upon S-phase entry; this extrusion is reversible according to the authors. The report suggests that uncontrolled PARylation during replication could mislocalize PARP1 and thereby impede PARP1-dependent nuclear processes, whereas active dePARylation restrains such mislocalization and condensation.
The study frames PARG as an emerging therapeutic target in cancer and notes that the mechanisms behind PARG inhibitor efficacy are not fully understood. The findings here propose that part of PARGi activity results from promotion of PAR-driven PARP1 condensation, particularly under conditions of replication-associated PARylation such as defective Okazaki fragment maturation. The synergy between PARG inhibition and FEN1 co-inhibition suggests a potential combinatorial vulnerability: interfering with Okazaki fragment processing increases PARP1 condensation and cytotoxicity when dePARylation is compromised.
The source text is an abstract and does not report experimental details, quantitative measures, cell types, model systems, exact PARG inhibitors used, concentrations, timing, nor the assays employed to assess condensate composition, PARP1 residence time, extrusion dynamics, or cytotoxicity. Specific mechanistic steps beyond the high-level observations are not provided in the abstract. These methodological and quantitative details were not reported in the source abstract and would be necessary to evaluate translational potential and reproducibility.
The authors conclude that active dePARylation limits replication-driven condensation of PARP1, preventing mislocalization and aberrant condensate formation during DNA damage and S phase. They identify Okazaki fragment maturation as a replication process that, when dysregulated or combined with dePARylation impairment, becomes a targetable vulnerability that enhances PAR-driven condensation and PARGi cytotoxicity. Further experimental detail would be required to assess therapeutic strategies and to translate these mechanistic insights into clinical approaches.